DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Junyong | ko |
dc.contributor.author | Jeong, Moonkyoung | ko |
dc.contributor.author | Park, Ji-Ho | ko |
dc.date.accessioned | 2023-12-22T01:00:43Z | - |
dc.date.available | 2023-12-22T01:00:43Z | - |
dc.date.created | 2023-08-22 | - |
dc.date.issued | 2023-12 | - |
dc.identifier.citation | CLINICAL AND EXPERIMENTAL MEDICINE, v.23, no.8, pp.5025 - 5037 | - |
dc.identifier.issn | 1591-8890 | - |
dc.identifier.uri | http://hdl.handle.net/10203/316849 | - |
dc.description.abstract | Despite the success of chimeric antigen receptor (CAR) T cells in hematologic malignancies, adoptive cell therapy (ACT) has not been effective in treating solid tumors. Here, we developed an inflammatory macrophage-based ACT to effectively treat solid tumors. We engineered inflammatory macrophages to enhance their antitumor activities, including proinflammatory cytokine secretion and co-stimulatory molecule expression by co-activating toll-like receptor and stimulator of interferon genes signaling pathways. Engineered macrophages maintain an inflammatory phenotype after their adoptive transfer into the anti-inflammatory tumor microenvironment (TME), whereas conventional inflammatory macrophages prepared using interferon-& gamma; treatment are repolarized to an anti-inflammatory phenotype. In a mouse melanoma model, intratumoral adoptive transfer of engineered macrophages showed robust tumor growth inhibition by increasing CD8(+) T cells in the TME and tumor antigen-specific CD8(+) T cells in the blood. This study demonstrated that engineered inflammatory macrophages have potential as an effective ACT for treating solid tumors. | - |
dc.language | English | - |
dc.publisher | SPRINGER-VERLAG ITALIA SRL | - |
dc.title | Intratumoral adoptive transfer of inflammatory macrophages engineered by co-activating TLR and STING signaling pathways exhibits robust antitumor activity | - |
dc.type | Article | - |
dc.identifier.wosid | 001042767200002 | - |
dc.identifier.scopusid | 2-s2.0-85166675058 | - |
dc.type.rims | ART | - |
dc.citation.volume | 23 | - |
dc.citation.issue | 8 | - |
dc.citation.beginningpage | 5025 | - |
dc.citation.endingpage | 5037 | - |
dc.citation.publicationname | CLINICAL AND EXPERIMENTAL MEDICINE | - |
dc.identifier.doi | 10.1007/s10238-023-01157-3 | - |
dc.contributor.localauthor | Park, Ji-Ho | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Cell therapy | - |
dc.subject.keywordAuthor | Inflammatory macrophages | - |
dc.subject.keywordAuthor | Solid tumors | - |
dc.subject.keywordAuthor | Pattern-recognition receptor signaling pathways | - |
dc.subject.keywordAuthor | Cancer immunotherapy | - |
dc.subject.keywordPlus | PHASE-I TRIAL | - |
dc.subject.keywordPlus | BLOOD MONOCYTES | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | NITRIC-OXIDE | - |
dc.subject.keywordPlus | T-CELLS | - |
dc.subject.keywordPlus | INNATE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | GLIOBLASTOMA | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.